 Connection
Charles Daley to Lung Diseases
This is a "connection" page, showing publications Charles Daley has written about Lung Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
6.293 |
|
|
|
-
Nguyen MH, Daley CL. Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start? Clin Chest Med. 2023 12; 44(4):771-783.
Score: 0.577
-
Daley CL, Winthrop KL. Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management. J Infect Dis. 2020 08 20; 222(Suppl 4):S199-S211.
Score: 0.470
-
Holt MR, Kasperbauer SH, Daley CL. Serial sputum induction in nontuberculous mycobacterial pulmonary disease. Eur Respir J. 2020 06; 55(6).
Score: 0.463
-
Holt MR, Kasperbauer SH, Koelsch TL, Daley CL. Similar characteristics of nontuberculous mycobacterial pulmonary disease in men and women. Eur Respir J. 2019 07; 54(1).
Score: 0.435
-
Daley CL, Olivier KN. ALIS (Amikacin Liposome Inhalation Suspension): The Beginning of a Wonderland? Am J Respir Crit Care Med. 2018 12 15; 198(12):1473-1475.
Score: 0.418
-
Koh WJ, Jeong BH, Jeon K, Park HY, Kim SY, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL. Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2015 Aug; 59(8):4994-6.
Score: 0.326
-
Kitada S, Levin A, Hiserote M, Harbeck RJ, Czaja CA, Huitt G, Kasperbauer SH, Daley CL. Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA. Eur Respir J. 2013 Aug; 42(2):454-60.
Score: 0.273
-
Cattamanchi A, Nahid P, Marras TK, Gotway MB, Lee TJ, Gonzalez LC, Morris A, Webb WR, Osmond DH, Daley CL. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection. Chest. 2008 Apr; 133(4):875-80.
Score: 0.197
-
Henkle E, Quittner AL, Dieckmann NF, Franklin H, Brunton AE, Daley CL, Winthrop KL. Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium avium Complex Pulmonary Disease. Chest. 2023 07; 164(1):53-64.
Score: 0.140
-
Kumar K, Daley CL, Griffith DE, Loebinger MR. Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments. Eur Respir Rev. 2022 Mar 31; 31(163).
Score: 0.130
-
Lange C, B?ttger EC, Cambau E, Griffith DE, Guglielmetti L, van Ingen J, Knight SL, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, Wagner D, Winthrop K, Daley CL. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022 07; 22(7):e178-e190.
Score: 0.130
-
van Ingen J, Aliberti S, Andrejak C, Chalmers JD, Codecasa LR, Daley CL, Hasegawa N, Griffith DE, Hoefsloot W, Huitt G, Jarand J, Jhun BW, Loebinger MR, Marras TK, Morimoto K, Polverino E, Ringshausen FC, Santin M, Thomson R, Wagner D, Wallace RJ, Winthrop KL, Yim JJ. Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey. Clin Infect Dis. 2021 07 01; 73(1):e256-e259.
Score: 0.125
-
Kang N, Jeon K, Kim H, Kwon OJ, Huh HJ, Lee NY, Daley CL, Koh WJ, Jhun BW. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease. Chest. 2021 08; 160(2):436-445.
Score: 0.122
-
Kurz SG, Zha BS, Herman DD, Holt MR, Daley CL, Ruminjo JK, Thomson CC. Summary for Clinicians: 2020 Clinical Practice Guideline Summary for the Treatment of Nontuberculous Mycobacterial Pulmonary Disease. Ann Am Thorac Soc. 2020 09; 17(9):1033-1039.
Score: 0.118
-
Han SA, Jhun BW, Kim SY, Moon SM, Yang B, Kwon OJ, Daley CL, Shin SJ, Koh WJ. miRNA Expression Profiles and Potential as Biomarkers in Nontuberculous Mycobacterial Pulmonary Disease. Sci Rep. 2020 02 21; 10(1):3178.
Score: 0.113
-
Jhun BW, Moon SM, Jeon K, Kwon OJ, Yoo H, Carriere KC, Huh HJ, Lee NY, Shin SJ, Daley CL, Koh WJ. Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. Eur Respir J. 2020 01; 55(1).
Score: 0.112
-
Kwak N, Dalcolmo MP, Daley CL, Eather G, Hasegawa N, Koh WJ, Thomson R, van Ingen J, Yim JJ. Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics? Eur Respir J. 2019 11; 54(5).
Score: 0.112
-
Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, Jhun BW, Koh WJ, Namkoong H, Park J, Thomson R, van Ingen J, Zweijpfenning SMH, Yim JJ. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J. 2019 07; 54(1).
Score: 0.109
-
Tortoli E, Brown-Elliott BA, Chalmers JD, Cirillo DM, Daley CL, Emler S, Floto RA, Garcia MJ, Hoefsloot W, Koh WJ, Lange C, Loebinger M, Maurer FP, Morimoto K, Niemann S, Richter E, Turenne CY, Vasireddy R, Vasireddy S, Wagner D, Wallace RJ, Wengenack N, van Ingen J. Same meat, different gravy: ignore the new names of mycobacteria. Eur Respir J. 2019 Jul; 54(1).
Score: 0.109
-
Kwon YS, Daley CL, Koh WJ. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches. Expert Rev Respir Med. 2019 09; 13(9):851-861.
Score: 0.109
-
Moon SM, Jhun BW, Daley CL, Koh WJ. Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease. Eur Respir J. 2019 05; 53(5).
Score: 0.108
-
Moon SM, Jhun BW, Baek SY, Kim S, Jeon K, Ko RE, Shin SH, Lee H, Kwon OJ, Huh HJ, Ki CS, Lee NY, Chung MJ, Lee KS, Shin SJ, Daley CL, Koh WJ. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. Respir Med. 2019 05; 151:1-7.
Score: 0.107
-
Moon SM, Choe J, Jhun BW, Jeon K, Kwon OJ, Huh HJ, Lee NY, Daley CL, Koh WJ. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease. Respir Med. 2019 03; 148:37-42.
Score: 0.105
-
Jhun BW, Kim SY, Moon SM, Jeon K, Kwon OJ, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Koh WJ. Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med. 2018 11 15; 198(10):1322-1330.
Score: 0.104
-
Shin SH, Jhun BW, Kim SY, Choe J, Jeon K, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Koh WJ. Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex. Antimicrob Agents Chemother. 2018 10; 62(10).
Score: 0.103
-
Henkle E, Aksamit TR, Daley CL, Griffith DE, O'Donnell AE, Quittner AL, Malanga E, Prieto D, Leitman A, Winthrop KL. US Patient-Centered Research Priorities and Roadmap for Bronchiectasis. Chest. 2018 11; 154(5):1016-1023.
Score: 0.101
-
van Ingen J, Aksamit T, Andrejak C, B?ttger EC, Cambau E, Daley CL, Griffith DE, Guglielmetti L, Holland SM, Huitt GA, Koh WJ, Lange C, Leitman P, Marras TK, Morimoto K, Olivier KN, Santin M, Stout JE, Thomson R, Tortoli E, Wallace RJ, Winthrop KL, Wagner D. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J. 2018 03; 51(3).
Score: 0.099
-
Jhun BW, Moon SM, Kim SY, Park HY, Jeon K, Kwon OJ, Huh HJ, Ki CS, Lee NY, Chung MJ, Lee KS, Shin SJ, Daley CL, Koh WJ. Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2018 02; 62(2).
Score: 0.098
-
Koh WJ, Moon SM, Kim SY, Woo MA, Kim S, Jhun BW, Park HY, Jeon K, Huh HJ, Ki CS, Lee NY, Chung MJ, Lee KS, Shin SJ, Daley CL, Kim H, Kwon OJ. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017 09; 50(3).
Score: 0.096
-
Choi H, Kim SY, Kim DH, Huh HJ, Ki CS, Lee NY, Lee SH, Shin S, Shin SJ, Daley CL, Koh WJ. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease. Antimicrob Agents Chemother. 2017 10; 61(10).
Score: 0.096
-
Yang B, Jhun BW, Moon SM, Lee H, Park HY, Jeon K, Kim DH, Kim SY, Shin SJ, Daley CL, Koh WJ. Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease. Antimicrob Agents Chemother. 2017 06; 61(6).
Score: 0.094
-
Choi H, Kim SY, Lee H, Jhun BW, Park HY, Jeon K, Kim DH, Huh HJ, Ki CS, Lee NY, Lee SH, Shin SJ, Daley CL, Koh WJ. Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease. Antimicrob Agents Chemother. 2017 02; 61(2).
Score: 0.092
-
Koh WJ, Jeong BH, Kim SY, Jeon K, Park KU, Jhun BW, Lee H, Park HY, Kim DH, Huh HJ, Ki CS, Lee NY, Kim HK, Choi YS, Kim J, Lee SH, Kim CK, Shin SJ, Daley CL, Kim H, Kwon OJ. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. Clin Infect Dis. 2017 Feb 01; 64(3):309-316.
Score: 0.090
-
Henkle E, Aksamit T, Barker A, Daley CL, Griffith D, Leitman P, Leitman A, Malanga E, Marras TK, Olivier KN, Prevots DR, Prieto D, Quittner AL, Skach W, Walsh JW, Winthrop KL. Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. Ann Am Thorac Soc. 2016 09; 13(9):S379-84.
Score: 0.089
-
Park HY, Jeong BH, Chon HR, Jeon K, Daley CL, Koh WJ. Lung Function Decline According to Clinical Course in Nontuberculous Mycobacterial Lung Disease. Chest. 2016 Dec; 150(6):1222-1232.
Score: 0.088
-
Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, Chimara E, Churchyard G, Cias R, Daza R, Daley CL, Dekhuijzen PN, Domingo D, Drobniewski F, Esteban J, Fauville-Dufaux M, Folkvardsen DB, Gibbons N, G?mez-Mampaso E, Gonzalez R, Hoffmann H, Hsueh PR, Indra A, Jagielski T, Jamieson F, Jankovic M, Jong E, Keane J, Koh WJ, Lange B, Leao S, Macedo R, Manns?ker T, Marras TK, Maugein J, Milburn HJ, Mlink? T, Morcillo N, Morimoto K, Papaventsis D, Palenque E, Paez-Pe?a M, Piersimoni C, Polanov? M, Rastogi N, Richter E, Ruiz-Serrano MJ, Silva A, da Silva MP, Simsek H, van Soolingen D, Szab? N, Thomson R, T?rtola Fernandez T, Tortoli E, Totten SE, Tyrrell G, Vasankari T, Villar M, Walkiewicz R, Winthrop KL, Wagner D. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013 Dec; 42(6):1604-13.
Score: 0.071
-
Collard HR, Morris A, Daley CL, Humbert M, Meyer KC. Clinical year in review IV: HIV, mycobacterial disease, pulmonary hypertension, and interstitial lung disease. Proc Am Thorac Soc. 2012 Oct; 9(4):204-9.
Score: 0.068
-
Heffner JE, Holgate ST, Chung KF, Niederman MS, Daley CL, Jett JR, Stradling JR, Wells AU, Light RW, Tapson VF, Hansell DM, Provonost PJ, Lee YC. Road ahead to respiratory health: experts chart future research directions. Respirology. 2009 Jul; 14(5):625-36.
Score: 0.053
-
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Winthrop K. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15; 175(4):367-416.
Score: 0.046
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|